Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Hager

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Bioorganic & Medicinal Chemistry Letters|October 29, 2008
Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitorJoseph E Payne, Céline Bonnefous, Christian A Hassig, et al.
EMBO Molecular Medicine|May 18, 2012
DIAPH3 governs the cellular transition to the amoeboid tumour phenotypeMartin H Hager, Samantha Morley, Diane R Bielenberg, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2008
Alpha-mercaptoketone based histone deacetylase inhibitorsPaul L Wash, Timothy Z Hoffman, Brandon M Wiley, et al.
Molecular and Cellular Biology|August 15, 2003
Of mice and MEN1: Insulinomas in a conditional mouse knockoutJudy S Crabtree, Peter C Scacheri, Jerrold M Ward, et al.
The American Journal of Pathology|October 2, 2012
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic diseaseDolores Di Vizio, Matteo Morello, Andrew C Dudley, et al.
Journal of Medicinal Chemistry|August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast CancerJohnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry|April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer XenograftsAndiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Bioorganic & Medicinal Chemistry Letters|October 29, 2008
Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitorJoseph E Payne, Céline Bonnefous, Christian A Hassig, et al.
EMBO Molecular Medicine|May 18, 2012
DIAPH3 governs the cellular transition to the amoeboid tumour phenotypeMartin H Hager, Samantha Morley, Diane R Bielenberg, et al.
Bioorganic & Medicinal Chemistry Letters|October 29, 2008
Alpha-mercaptoketone based histone deacetylase inhibitorsPaul L Wash, Timothy Z Hoffman, Brandon M Wiley, et al.
Molecular and Cellular Biology|August 15, 2003
Of mice and MEN1: Insulinomas in a conditional mouse knockoutJudy S Crabtree, Peter C Scacheri, Jerrold M Ward, et al.
The American Journal of Pathology|October 2, 2012
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic diseaseDolores Di Vizio, Matteo Morello, Andrew C Dudley, et al.
Journal of Medicinal Chemistry|August 9, 2018
Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast CancerJohnny Nagasawa, Steven Govek, Mehmet Kahraman, et al.
ACS Medicinal Chemistry Letters|January 19, 2019
Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927Mehmet Kahraman, Steven P Govek, Johnny Y Nagasawa, et al.
Bioorganic & Medicinal Chemistry Letters|October 15, 2015
Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Johnny Y Nagasawa, Karensa L Douglas, et al.
Journal of Medicinal Chemistry|April 17, 2015
Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer XenograftsAndiliy Lai, Mehmet Kahraman, Steven Govek, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2018
Selective estrogen receptor degraders with novel structural motifs induce regression in a tamoxifen-resistant breast cancer xenograftSteven P Govek, Celine Bonnefous, Jackaline D Julien, et al.
Pageof 17